Rapid and prolonged immunologic-therapeutic
The present invention shows that intranasal administration of E1/E3-defective adenovirus particles may confer rapid and broad protection against viral and bacterial pathogens in a variety of disease settings. Protective responses lasted for many weeks in a single-dose regimen in animal models. When a pathogen-derived antigen gene was inserted into the E1/E3-defective adenovirus genome, the antigen-induced protective immunity against the specific pathogen was elicited before the adenovirus-mediated protective response declined away, thus conferring rapid, prolonged, and seamless protection against pathogens. In addition to E1/E3-defective adenovirus, other bioengineered non-replicating vectors encoding pathogen-derived antigens may also be developed into a new generation of rapid and prolonged immunologic-therapeutic (RAPIT).
1. A method for inducing a rapid and prolonged response against respiratory pathogens in a mammalian subject in need thereof comprising administering intranasally an effective amount of at least 10 7 infectious units (ifu) of an empty E1 and/or E3 deleted adenovirus vector, without encoding a heterologous antigen, wherein the response begins within about twenty four hours of administration and lasts at least 21 days.
2. The method of claim 1 , wherein the respiratory pathogen is a virus.
3. The method of claim 2 , wherein the virus is a orthomyxovirus, a paramyxovirus, a rhinovirus or a coronavirus.
4. The method of claim 2 , wherein the virus is an influenza virus, a respiratory syncytial virus (RSV), a common cold virus or a measles virus.
5. The method of claim 4 , wherein the common cold virus is a rhinovirus or a coronavirus.
6. The method of claim 1 , wherein the respiratory pathogen is a bacterium.
7. The method of claim 6 , wherein the bacterium is selected from the group consisting of Bacillus, Mycobacterium, Staphylococcus, Streptococcus, Pseudomonas, Klebsiella, Haemophilus , and Mycoplasma.
8. The method of claim 7 , wherein the bacterium is Bacillus anthracis.
9. The method of claim 1 , wherein the respiratory pathogen is a fungus.
10. The method of claim 9 , wherein the fungus is Aspergillus.
11. The method of claim 1 , further comprising administering intranasally a second E1 and/or E3 deleted adenovirus vector in an effective amount of at least 10 7 infectious units (ifu), wherein the second adenovirus encodes a heterologous antigen, providing a drug-vaccine duo regimen.
12. The method of claim 11 , wherein the heterologous antigen is encoded by a heterologous nucleic acid molecule selected from an influenza virus, a respiratory syncytial virus (RSV) or Bacillus anthracis.
13. The method of claim 11 , wherein the second E1 and/or E3 deleted adenovirus vector is administered simultaneously with the empty E1 and/or E3 deleted adenovirus vector.
14. The method of claim 1 wherein the subject in need thereof is an adult.
15. The method of claim 1 wherein the subject in need thereof is a child.
16. The method of claim 1 wherein the subject in need thereof is an immunocompromised patient.
17. The method of claim 1 comprising at least two steps of administering.
18. The method of claim 17 wherein the administering is about 20 days apart, about 25 days apart, about 30 days apart, about 35 days apart, about 40 days apart, about 41 days apart, about 42 days apart, about 43 days apart, about 44 days apart, about 45 days apart, about 46 days apart, about 47 days apart, about 48 days apart, about 49 days apart or about 50 days apart.
19. The method of claim 1 wherein the adenovirus is a human adenovirus.
20. The method of claim 1 wherein the adenovirus is a bovine adenovirus, a canine adenovirus, a non-human primate adenovirus, a chicken adenovirus, or a porcine or swine adenovirus.
21. The method of claim 1 , wherein the protective response lasts at least 47 days.
22. A method for inducing a rapid and prolonged protective response against respiratory pathogens in a mammalian subject in need thereof comprising;
administering intranasally a first adenovirus vector in an effective amount of at least 10 7 infectious units (ifu) wherein the first adenovirus vector is an empty, without encoding a heterologous antigen, E1 and/or E3 deleted adenovirus vector; and
administering intranasally a second adenovirus vector in an effective amount of at least 10 7 infectious units (ifu) wherein the second adenovirus vector is an E1 and/or E3 deleted adenovirus vector encoding a heterologous antigen,
wherein the protective response begins within about twenty four hours of administration and lasts at least 21 days.
23. The method of claim 22 , wherein the first adenovirus vector is administered simultaneously with the second adenovirus vector.
24. The method of claim 22 , wherein first adenovirus vector and the second adenovirus vector are administered sequentially.
25. The method of claim 22 , wherein the two administration steps are one dosage and the method further comprises administering a second dosage.
26. The method of claim 25 , wherein the first and second dosages are administered about 20 days apart, about 25 days apart, about 30 days apart, about 35 days apart, about 40 days apart, about 41 days apart, about 42 days apart, about 43 days apart, about 44 days apart, about 45 days apart, about 46 days apart, about 47 days apart, about 48 days apart, about 49 days apart or about 50 days apart.
27. The method of claim 22 , wherein the respiratory pathogen is a virus.
28. The method of claim 27 , wherein the virus is a orthomyxovirus, a paramyxovirus, a rhinovirus or a coronavirus.
29. The method of claim 27 , wherein the virus is an influenza virus, a respiratory syncytial virus (RSV), a common cold virus or a measles virus.
30. The method of claim 22 , wherein the respiratory pathogen is a bacterium.
31. The method of claim 27 , wherein the bacterium is selected from the group consisting of Bacillus, Mycobacterium, Staphylococcus, Streptococcus, Pseudomonas, Klebsiella, Haemophilus , and Mycoplasma.
32. The method of claim 22 , wherein the protective response lasts at least 47 days.
33. A method for inducing a rapid and prolonged protective response against influenza virus in a mammalian subject in need thereof comprising;
administering intranasally a first adenovirus vector in an effective amount of at least 10 7 infectious units (ifu) wherein the first adenovirus vector is an empty, without encoding a heterologous antigen, E1 and/or E3 deleted adenovirus vector; and
administering intranasally a second adenovirus vector in an effective amount of at least 10 7 infectious units (ifu) wherein the second adenovirus vector is an E1 and/or E3 deleted adenovirus vector encoding an influenza virus antigen,
wherein the protective response begins within about twenty four hours of administration and lasts at least 21 days.